Endotoxin Diagnosis
High Density Lipoprotein (HDL)
Men and women in the generalpopulation with extreme high HDL cholesterol paradoxically have high all-causemortality. Madsen, Christian M., Anette Varbo, and Børge G.Nordestgaard. "Extreme High High-Density Lipoprotein Cholesterol IsParadoxically Associated with High Mortality in Men and Women: Two ProspectiveCohort Studies." European Heart Journal 38, no. 32 (August 21, 2017): 2478–86. https://doi.org/10.1093/eurheartj/ehx163.
Comment: A well-forgotten fact that most doctors learn in medical school is that the main role of HDL is to carry toxins (and cholesterol) from peripheral tissues back to the liver. One of those toxins is, of course, endo-toxin(LPS)! Thus, is a person has an issue with low-grade endotoxemia their HDL isusually in the upper 25% of the "normal" range, or slightly above. Doctors lovesuch numbers, but they forget that the population where such HDL levels are most commonly observed are chronic alcoholics – hardly the epitome of health. Other studies have also shown HDL levels to be predictive of severity ofHIV/AIDS, hepatitis, several types of cancer, and (most worryingly) all-cause mortality. As such, monitoring HDL levels may be an easy way to monitor yourlow-grade inflammation status. http://haidut.me/?p=1684
Why Raising Good Cholesterol Doesn’t Always Help the Heart – TIME Magazine. 4/4/2016. Link: https://time.com/4279691/hdl-cholesterol-drugs-heart
Serum lipopolysaccharide (LPS)
Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated thedeterminants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke.The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated.
Leskelä, Jaakko, Milla Pietiäinen, Anton Safer, MarkkuLehto, Jari Metso, Ernst Malle, Florian Buggle, et al. "SerumLipopolysaccharide Neutralizing Capacity in Ischemic Stroke." Edited by AlbertoG Passi. PLOS ONE 15, no. 2 (February 21, 2020): e0228806. https://doi.org/10.1371/journal.pone.0228806.